OPKO’s growth strategy includes investing in early-stage comInteresting read. Maybe Bencro knows something we do not as of yet? He has already shared some great points as to why Theralase is a good fit for OPKO!!
"OPKO’s growth strategy includes investing in early-stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder." Would like to see Theralase On the top of that list soon.. 
Some of the Strategic Investments:
ARNO Therapeutics ARNO Therapeutics (Flemington, NJ), a publicly traded biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. ARNO has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds
are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.
More »
Cocrystal Pharma Cocrystal Pharma (Bothell, WA), a publicly traded biopharmaceutical company focused on the discovery and development of novel small molecule antiviral therapeutics tailored for the treatment of serious and chronic viral diseases,
It is currently developing oral, small molecule, antiviral therapeutics for Hepatitis C and influenza.
More »
MABVAX MABVAX (San Diego, CA) Mabvax Therapeutics is
a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer.
More »
Pharmsynthez Pharmsynthez (St. Petersberg, Russia), a publicly traded pharmaceutical company that manufactures and markets medicines used in oncology, gynecology, viral diseases and tuberculosis, and
conducts clinical development of therapeutic vaccines and bio superiors.
More »
RXi Pharmaceuticals RXi Pharmaceuticals (Marlborough, MA), a publicly traded biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to “silence,” or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi’s first RNAi product candidate,
RXI-109,
entered into RXi’s first human clinical trial in 2012. RXI-109 targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
More »
Sevion Sevion (Bridgewater, NJ) acquired Fabrus (San Diego, CA) in May 2014 and is a publicly traded clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to kill cancer cells and protect healthy cells from premature death in disease models. Fabrus is an
early stage biotechnology company with next generation therapeutic antibody drug discovery and development capabilities that is using its proprietary antibody screening and engineering approach to discover promising lead compounds against several important oncology targets.
More »
Xenetic Biosciences Xenetic Biosciences, Inc.
is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Their proprietary drug development platforms include PolYXen, which enables biological drugs by improving their half-life. Xenetics lead investigational product candidates include FDA orphan designated oncology therapeutic XBIO-101 for the treatment of progesterone receptor negative endometrial cancer and a polysialyated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. Xenetic also is developing, in partnership with Shire plc, a product SHP656 (PSA Factor VII) for Hemophilia A.
More »
here is the link to the full listing....
https://www.opko.com/strategic-investments/overview/
good luck to all!!